Pharmaniaga Targets Local Production Of Nine NIP Vaccines
Pharmaniaga Berhad aims to locally produce nine of 11 National Immunisation Programme (NIP) vaccines, including polio vaccines through a partnership with Indonesia’s PT Bio Farma. Its first locally manufactured vaccine, PCV13, is targeted for late 2027.
Pharmaniaga aims to locally produce nine NIP vaccines, including polio, through a partnership with PT Bio Farma, targeting PCV13 by 2027.
Pharmaniaga plans to locally produce nine of 11 NIP vaccines with PT Bio Farma's collaboration.
Malaysia currently imports all vaccines, making its immunisation programme vulnerable.
PT Bio Farma has expertise in producing vaccines like BCG and polio.
Summarised automatically by AI from the original article by CodeBlue. AI can make mistakes, so check the original for details.
PUTRAJAYA, Oct 14 — Pharmaniaga Bhd is targeting local production of nine out of 11 vaccines under the National Immunisation Programme (NIP) as the pharmaceutical company seeks to reduce the country’s reliance on imported vaccines.
Pharmaniaga managing director Zulkifli Jafar said the company signed a memorandum of collaboration with Indonesia’s state-owned vaccine manufacturer PT Bio Farma on October 8 to strengthen Malaysia’s vaccine security and develop domestic manufacturing capabilities through technology transfer.
“Under the NIP, there are about 11 vaccines. We are currently looking at developing seven of them. But with our collaboration with PT Bio Farma, we can increase from seven to nine vaccines to be developed or manufactured locally,” Zulkifli told reporters on the sidelines of the PharmaView Expert Series 2026 here yesterday.
Read the full story on CodeBlueYou've read the opening, about 125 of 832 words. The full piece is published by CodeBlue.
AI summary IHH Healthcare protests AIA's exclusion of its consultants from the panel, claiming it's based on commercial reasons, not clinical or ethical grounds.
